Figure 5. Cooperative bactericidal activity elicited by JAR 41, individually or in combination with second anti-fHbp mAbs.

Panel a, strain H44/76 (fHbp ID 1, variant group 1). Panel b, mutant of strain H44/76 engineered to have lower expression of fHbp ID 1 as that of the wild-type strain (See Figure 4a). Panel c, strain 8047 (fHbp ID 77, variant group 2). BC_50%, concentration of mAb (µg/ml) resulting in 50% decrease in CFU/ml after 1 hr incubation with human complement, compared to time 0. The combinations contained 1∶1 mixtures (i.e, BC_50% of 1 µg/ml contained 0.5 µg/ml of each of the mAbs in the combination). The anti-capsular mAb (SEAM 12)⁴¹ or anti-PorA mAbs (P1.7, panels a and b; or P1.2, panel c) served as positive controls. Error bars represent range of results from two to three independent assays.